ResearchIn-Press PreviewAgingImmunologyInfectious disease
Open Access |
10.1172/jci.insight.195618
1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands
2GSK, Rixensart, Belgium
3GSK, Bengaluru, India
4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands
Find articles by
Kilic, G.
in:
PubMed
|
Google Scholar
|
1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands
2GSK, Rixensart, Belgium
3GSK, Bengaluru, India
4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands
Find articles by Taks, E. in: PubMed | Google Scholar
1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands
2GSK, Rixensart, Belgium
3GSK, Bengaluru, India
4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands
Find articles by Helder, L. in: PubMed | Google Scholar
1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands
2GSK, Rixensart, Belgium
3GSK, Bengaluru, India
4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands
Find articles by Dulfer, E. in: PubMed | Google Scholar
1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands
2GSK, Rixensart, Belgium
3GSK, Bengaluru, India
4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands
Find articles by Geckin, B. in: PubMed | Google Scholar
1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands
2GSK, Rixensart, Belgium
3GSK, Bengaluru, India
4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands
Find articles by van Emst, L. in: PubMed | Google Scholar
1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands
2GSK, Rixensart, Belgium
3GSK, Bengaluru, India
4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands
Find articles by
Lemmers, H.
in:
PubMed
|
Google Scholar
|
1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands
2GSK, Rixensart, Belgium
3GSK, Bengaluru, India
4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands
Find articles by Berrè, S. in: PubMed | Google Scholar
1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands
2GSK, Rixensart, Belgium
3GSK, Bengaluru, India
4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands
Find articles by Biswas, A. in: PubMed | Google Scholar
1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands
2GSK, Rixensart, Belgium
3GSK, Bengaluru, India
4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands
Find articles by Ozturk, M. in: PubMed | Google Scholar
1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands
2GSK, Rixensart, Belgium
3GSK, Bengaluru, India
4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands
Find articles by Negishi, Y. in: PubMed | Google Scholar
1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands
2GSK, Rixensart, Belgium
3GSK, Bengaluru, India
4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands
Find articles by Burny, W. in: PubMed | Google Scholar
1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands
2GSK, Rixensart, Belgium
3GSK, Bengaluru, India
4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands
Find articles by Buonocore, S. in: PubMed | Google Scholar
1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands
2GSK, Rixensart, Belgium
3GSK, Bengaluru, India
4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands
Find articles by ten Oever, J. in: PubMed | Google Scholar
1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands
2GSK, Rixensart, Belgium
3GSK, Bengaluru, India
4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands
Find articles by Mhlanga, M. in: PubMed | Google Scholar
1Department of Internal Medicine and Radboud Community for Infec7ous Disease, Radboud University Medical Center, Nijmegen, Netherlands
2GSK, Rixensart, Belgium
3GSK, Bengaluru, India
4Department of Cell Biology, Faculty of Science, Radboud University, Nijmegen, Netherlands
Find articles by Netea, M. in: PubMed | Google Scholar
Published June 2, 2026 - More info
Immunosenescence, the biological aging of the immune system, leads to dysregulated immune responses, increasing susceptibility to infections and reducing vaccine efficacy in older adults, as seen with flu vaccines. In contrast, the AS01-adjuvanted recombinant herpes zoster vaccine (RZV) maintains high and sustained efficacy, offering 82% protection against herpes zoster at 11-years post-vaccination, in individuals over 50. To identify factors impacting age-dependent vaccine efficacy, we conducted a randomized, partially placebo-controlled clinical study. Young adults (18-35 years, n=84) were randomized 3:3:1:1 to receive either RZV, an inactivated quadrivalent seasonal influenza vaccine (IIV4), placebo for RZV or placebo for IIV4, while older adults (≥60, n=63) were randomized 1:1 to receive RZV or IIV4. RZV elicited robust antibody production, antigen-specific polyfunctional CD4+ T cell responses and IFN-γ from PBMCs in both age groups, while IIV4 increased antibody responses, but induced fewer antigen-specific CD4+ T cells and no elevation of IFN-γ from PBMCs. Interestingly, RZV reduced systemic inflammation in older adults, particularly after the second injection. Baseline inflammation negatively correlated with antibody production and IFN-γ response, especially after RZV. Our findings suggest that RZV may help overcome immunosenescence by enhancing cellular responses and potentially decreasing systemic inflammation, deserving further investigation into the underlying molecular mechanisms.